Last 12 months
Inside the activity.
3 purchase rows · 4 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 3 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 4 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2022 Filed May 12, 2022 20:30 UTC |
Aftab BlakeChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $12.18 | $0.00 |
DisclosureSEC source: 0001209191-22-028567 · doc4.xml · derivative · entry 1 Aftab Blake · CIK 0001886986 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-05-09 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on April 29, 2023 and, thereafter, the remainder of the shares shall vest in 36 equal monthly installments, provided that the Reporting Person maintains a service relationship with the Company as of the applicable vesting dates. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 22:23 UTC |
Galimi FrancescoSVP & Chief Medical Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,775 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0001209191-22-023285 · doc4.xml · derivative · entry 12 Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,625 Underlying: Common Stock · 1,775 shares Expires 2031-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021. F5 · derivative.exercise_date: A total of 28,400 shares subject to an employee stock option were granted on February 12, 2021, with 1/48th of the shares vesting on each of the next forty-eight (48) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting dates. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 22:23 UTC |
Galimi FrancescoSVP & Chief Medical Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 168 | Not disclosed Strike: $5.97 | Not disclosed |
DisclosureSEC source: 0001209191-22-023285 · doc4.xml · derivative · entry 11 Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,652 Underlying: Common Stock · 168 shares Expires 2029-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021. F3 · price: Received in exchange for an employee stock option to acquire 1,035,685 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), for $0.740 per share in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc." F2 · derivative.exercise_date: A total of 128,424 shares subject to an employee stock option were received as described in footnote (3). 25% of the shares vested on September 23, 2020, and 1/36th of the remaining unvested shares vest on each of the next thirty-six (36) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting date. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 22:23 UTC |
Galimi FrancescoSVP & Chief Medical Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,036 | $0.00 Strike: $13.27 | $0.00 |
DisclosureSEC source: 0001209191-22-023285 · doc4.xml · derivative · entry 10 Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,964 Underlying: Common Stock · 6,036 shares Expires 2031-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021. F4 · derivative.exercise_date: A total of 80,000 shares subject to an employee stock option were granted on January 13, 2021, with 1/48th of the shares vesting on each of the next forty-eight (48) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting dates. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 22:23 UTC |
Galimi FrancescoSVP & Chief Medical Officer
|
SaleCommon Stock | 1,775 | $21.00 | $37,275.00 |
DisclosureSEC source: 0001209191-22-023285 · doc4.xml · nonDerivative · entry 8 Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,917 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 22:23 UTC |
Galimi FrancescoSVP & Chief Medical Officer
|
Exercise / conversionCommon Stock | 1,775 | $16.82 | $29,855.50 |
DisclosureSEC source: 0001209191-22-023285 · doc4.xml · nonDerivative · entry 7 Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 22:23 UTC |
Galimi FrancescoSVP & Chief Medical Officer
|
SaleCommon Stock | 168 | $21.00 | $3,528.00 |
DisclosureSEC source: 0001209191-22-023285 · doc4.xml · nonDerivative · entry 6 Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,917 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 22:23 UTC |
Galimi FrancescoSVP & Chief Medical Officer
|
Exercise / conversionCommon Stock | 168 | $5.97 | $1,002.96 |
DisclosureSEC source: 0001209191-22-023285 · doc4.xml · nonDerivative · entry 5 Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 22:23 UTC |
Galimi FrancescoSVP & Chief Medical Officer
|
SaleCommon Stock | 6,036 | $21.00 | $126,756.00 |
DisclosureSEC source: 0001209191-22-023285 · doc4.xml · nonDerivative · entry 4 Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,917 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 22:23 UTC |
Galimi FrancescoSVP & Chief Medical Officer
|
Exercise / conversionCommon Stock | 6,036 | $13.27 | $80,097.72 |
DisclosureSEC source: 0001209191-22-023285 · doc4.xml · nonDerivative · entry 3 Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 22:23 UTC |
Galimi FrancescoSVP & Chief Medical Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,621 | Not disclosed Strike: $5.97 | Not disclosed |
DisclosureSEC source: 0001209191-22-023285 · doc4.xml · derivative · entry 9 Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,820 Underlying: Common Stock · 7,621 shares Expires 2029-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021. F3 · price: Received in exchange for an employee stock option to acquire 1,035,685 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), for $0.740 per share in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc." F2 · derivative.exercise_date: A total of 128,424 shares subject to an employee stock option were received as described in footnote (3). 25% of the shares vested on September 23, 2020, and 1/36th of the remaining unvested shares vest on each of the next thirty-six (36) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting date. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 22:23 UTC |
Galimi FrancescoSVP & Chief Medical Officer
|
SaleCommon Stock | 7,621 | $21.00 | $160,041.00 |
DisclosureSEC source: 0001209191-22-023285 · doc4.xml · nonDerivative · entry 2 Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,917 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 22:23 UTC |
Galimi FrancescoSVP & Chief Medical Officer
|
Exercise / conversionCommon Stock | 7,621 | $5.97 | $45,497.37 |
DisclosureSEC source: 0001209191-22-023285 · doc4.xml · nonDerivative · entry 1 Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:08 UTC |
Jakobovits AyaDirector
|
SaleCommon Stock | 2,000 | $14.00 | $28,000.00 |
DisclosureSEC source: 0001209191-22-018158 · doc4.xml · nonDerivative · entry 2 Jakobovits Aya · CIK 0001823901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 356,345 F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person. F3 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' son is the beneficiary. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:08 UTC |
Jakobovits AyaDirector
|
SaleCommon Stock | 2,000 | $14.00 | $28,000.00 |
DisclosureSEC source: 0001209191-22-018158 · doc4.xml · nonDerivative · entry 1 Jakobovits Aya · CIK 0001823901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 356,343 F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person. F2 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' daughter is the beneficiary. Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 23:10 UTC |
Jakobovits AyaDirector
|
SaleCommon Stock | 2,000 | $14.83 | $29,663.80 |
DisclosureSEC source: 0001209191-22-010952 · doc4.xml · nonDerivative · entry 2 Jakobovits Aya · CIK 0001823901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 358,345 F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.52 to $15.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' son is the beneficiary. Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 23:10 UTC |
Jakobovits AyaDirector
|
SaleCommon Stock | 2,000 | $14.83 | $29,663.80 |
DisclosureSEC source: 0001209191-22-010952 · doc4.xml · nonDerivative · entry 1 Jakobovits Aya · CIK 0001823901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 358,343 F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.52 to $15.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' daughter is the beneficiary. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:40 UTC |
Aftab BlakeChief Scientific Officer
|
Tax withholdingCommon Stock | 5,533 | $14.27 | $78,955.91 |
DisclosureSEC source: 0001209191-22-010485 · doc4.xml · nonDerivative · entry 2 Aftab Blake · CIK 0001886986 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,903 Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:40 UTC |
Aftab BlakeChief Scientific Officer
|
GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010485 · doc4.xml · nonDerivative · entry 1 Aftab Blake · CIK 0001886986 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,436 F1 · balance_after: The Reporting Person was issued 80,000 Restricted Stock Units ("RSUs") on October 12, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 13, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 32,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 12, 2022 and the second tranche vesting on October 12, 2023. A total of 48,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. On February 14, 2022, upon the occurrence of the second performance milestone, 16,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:41 UTC |
Healey DonChief Technology Officer
|
Tax withholdingCommon Stock | 5,533 | $14.27 | $78,955.91 |
DisclosureSEC source: 0001209191-22-010487 · doc4.xml · nonDerivative · entry 2 Healey Don · CIK 0001643067 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,934 Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:41 UTC |
Healey DonChief Technology Officer
|
GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010487 · doc4.xml · nonDerivative · entry 1 Healey Don · CIK 0001643067 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,467 F1 · balance_after: The Reporting Person was issued 80,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 32,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 48,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. On February 14, 2022, upon the occurrence of the second performance milestone, 16,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:36 UTC |
Galimi FrancescoSVP & Chief Medical Officer
|
Tax withholdingCommon Stock | 5,533 | $14.27 | $78,955.91 |
DisclosureSEC source: 0001209191-22-010483 · doc4.xml · nonDerivative · entry 2 Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,917 Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:36 UTC |
Galimi FrancescoSVP & Chief Medical Officer
|
GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010483 · doc4.xml · nonDerivative · entry 1 Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,450 F1 · balance_after: The Reporting Person was issued 80,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 32,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 48,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. On February 14, 2022, upon the occurrence of the second performance milestone, 16,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:33 UTC |
Harvey Brian NicholasChief Financial Officer
|
Tax withholdingCommon Stock | 4,696 | $14.27 | $67,011.92 |
DisclosureSEC source: 0001209191-22-010479 · doc4.xml · nonDerivative · entry 2 Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,608 Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:33 UTC |
Harvey Brian NicholasChief Financial Officer
|
GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010479 · doc4.xml · nonDerivative · entry 1 Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,304 F1 · balance_after: The Reporting Person was issued 80,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 32,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 48,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. On February 14, 2022, upon the occurrence of the second performance milestone, 16,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:31 UTC |
Schor ChenDirector · President & CEO
|
Tax withholdingCommon Stock | 21,288 | $14.27 | $303,779.76 |
DisclosureSEC source: 0001209191-22-010475 · doc4.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,424 Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:31 UTC |
Schor ChenDirector · President & CEO
|
GrantCommon Stock | 48,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010475 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,712 F1 · balance_after: The Reporting Person was issued 240,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 96,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 144,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. On February 14, 2022, upon the occurrence of the second performance milestone, 48,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| February 09, 2022 Filed Feb 14, 2022 22:28 UTC |
Jakobovits AyaDirector
|
SaleCommon Stock | 4,000 | $14.03 | $56,121.20 |
DisclosureSEC source: 0001209191-22-009417 · doc4.xml · nonDerivative · entry 6 Jakobovits Aya · CIK 0001823901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 360,345 F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' son is the beneficiary. Read SEC document |
| February 09, 2022 Filed Feb 14, 2022 22:28 UTC |
Jakobovits AyaDirector
|
SaleCommon Stock | 4,000 | $14.03 | $56,117.60 |
DisclosureSEC source: 0001209191-22-009417 · doc4.xml · nonDerivative · entry 5 Jakobovits Aya · CIK 0001823901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 360,343 F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' daughter is the beneficiary. Read SEC document |
| January 28, 2022 Filed Feb 2, 2022 01:50 UTC |
Galimi FrancescoSVP & Chief Medical Officer
|
Tax withholdingCommon Stock | 5,533 | $11.69 | $64,680.77 |
DisclosureSEC source: 0001209191-22-006142 · doc4.xml · nonDerivative · entry 2 Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,450 Read SEC document |
| January 28, 2022 Filed Feb 2, 2022 01:50 UTC |
Galimi FrancescoSVP & Chief Medical Officer
|
GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006142 · doc4.xml · nonDerivative · entry 1 Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,983 F1 · balance_after: The Reporting Person was issued 80,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 32,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 48,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. On January 28, 2022, upon the occurrence of the first performance milestone, 16,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| January 28, 2022 Filed Feb 2, 2022 01:48 UTC |
Healey DonChief Technology Officer
|
Tax withholdingCommon Stock | 5,533 | $11.69 | $64,680.77 |
DisclosureSEC source: 0001209191-22-006139 · doc4.xml · nonDerivative · entry 2 Healey Don · CIK 0001643067 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,467 Read SEC document |
| January 28, 2022 Filed Feb 2, 2022 01:48 UTC |
Healey DonChief Technology Officer
|
GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006139 · doc4.xml · nonDerivative · entry 1 Healey Don · CIK 0001643067 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 F1 · balance_after: The Reporting Person was issued 80,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 32,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 48,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. On January 28, 2022, upon the occurrence of the first performance milestone, 16,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| January 28, 2022 Filed Feb 2, 2022 01:44 UTC |
Aftab BlakeChief Scientific Officer
|
Tax withholdingCommon Stock | 5,564 | $11.69 | $65,043.16 |
DisclosureSEC source: 0001209191-22-006136 · doc4.xml · nonDerivative · entry 2 Aftab Blake · CIK 0001886986 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,436 Read SEC document |
| January 28, 2022 Filed Feb 2, 2022 01:44 UTC |
Aftab BlakeChief Scientific Officer
|
GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006136 · doc4.xml · nonDerivative · entry 1 Aftab Blake · CIK 0001886986 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 F1 · balance_after: The Reporting Person was issued 80,000 Restricted Stock Units ("RSUs") on October 12, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 13, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 32,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 12, 2022 and the second tranche vesting on October 12, 2023. A total of 48,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. On January 28, 2022, upon the occurrence of the first performance milestone, 16,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| January 28, 2022 Filed Feb 2, 2022 01:42 UTC |
Harvey Brian NicholasChief Financial Officer
|
Tax withholdingCommon Stock | 4,696 | $11.69 | $54,896.24 |
DisclosureSEC source: 0001209191-22-006134 · doc4.xml · nonDerivative · entry 2 Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,304 Read SEC document |
| January 28, 2022 Filed Feb 2, 2022 01:42 UTC |
Harvey Brian NicholasChief Financial Officer
|
GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006134 · doc4.xml · nonDerivative · entry 1 Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 F1 · balance_after: The Reporting Person was issued 80,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 32,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 48,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. On January 28, 2022, upon the occurrence of the first performance milestone, 16,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| January 28, 2022 Filed Feb 2, 2022 01:40 UTC |
Schor ChenDirector · President & CEO
|
Tax withholdingCommon Stock | 21,288 | $11.69 | $248,856.72 |
DisclosureSEC source: 0001209191-22-006132 · doc4.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,712 Read SEC document |
| January 28, 2022 Filed Feb 2, 2022 01:40 UTC |
Schor ChenDirector · President & CEO
|
GrantCommon Stock | 48,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006132 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,000 F1 · balance_after: The Reporting Person was issued 240,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 96,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 144,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. On January 28, 2022, upon the occurrence of the first performance milestone, 48,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:49 UTC |
Harvey Brian NicholasChief Financial Officer
|
GrantStock Option (Right to Buy · Derivative | 125,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001209191-22-002900 · doc4.xml · derivative · entry 1 Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-01-06 F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Grant Date, provided that the Reporting Person maintains a service relationship with the Company as of the applicable vesting dates. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:45 UTC |
Aftab BlakeChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001209191-22-002895 · doc4.xml · derivative · entry 1 Aftab Blake · CIK 0001886986 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-01-06 F1 · derivative.exercise_date: 25% of the shares shall vest on the first anniversary of January 7, 2022 and, thereafter, the remainder of the shares shall vest in 36 equal monthly installments, provided that the Reporting Person maintains a service relationship with the Company as of the applicable vesting dates. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:40 UTC |
Galimi FrancescoSVP & Chief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001209191-22-002880 · doc4.xml · derivative · entry 1 Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-01-06 F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Grant Date, provided that the Reporting Person maintains a service relationship with the Company as of the applicable vesting dates. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:33 UTC |
Healey DonChief Technology Officer
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001209191-22-002867 · doc4.xml · derivative · entry 1 Healey Don · CIK 0001643067 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-01-06 F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Grant Date, provided that the Reporting Person maintains a service relationship with the Company as of the applicable vesting dates. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:28 UTC |
Schor ChenDirector · President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 295,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001209191-22-002860 · doc4.xml · derivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,000 Underlying: Common Stock · 295,000 shares Expires 2032-01-06 F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Grant Date, provided that the Reporting Person maintains a service relationship with the Company as of the applicable vesting dates. Read SEC document |
| January 05, 2022 Filed Feb 14, 2022 22:28 UTC |
Jakobovits AyaDirector
|
SaleCommon Stock | 2,000 | $16.90 | $33,799.00 |
DisclosureSEC source: 0001209191-22-009417 · doc4.xml · nonDerivative · entry 4 Jakobovits Aya · CIK 0001823901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 364,345 F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.41 to $17.21. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' son is the beneficiary. Read SEC document |
| January 05, 2022 Filed Feb 14, 2022 22:28 UTC |
Jakobovits AyaDirector
|
SaleCommon Stock | 2,000 | $16.93 | $33,864.00 |
DisclosureSEC source: 0001209191-22-009417 · doc4.xml · nonDerivative · entry 3 Jakobovits Aya · CIK 0001823901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 364,343 F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.41 to $17.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' daughter is the beneficiary. Read SEC document |
| January 03, 2022 Filed Feb 14, 2022 22:28 UTC |
Jakobovits AyaDirector
|
SaleCommon Stock | 6,000 | $18.02 | $108,130.80 |
DisclosureSEC source: 0001209191-22-009417 · doc4.xml · nonDerivative · entry 2 Jakobovits Aya · CIK 0001823901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 366,345 F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' son is the beneficiary. Read SEC document |
| January 03, 2022 Filed Feb 14, 2022 22:28 UTC |
Jakobovits AyaDirector
|
SaleCommon Stock | 6,000 | $18.02 | $108,124.80 |
DisclosureSEC source: 0001209191-22-009417 · doc4.xml · nonDerivative · entry 1 Jakobovits Aya · CIK 0001823901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 366,343 F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' daughter is the beneficiary. Read SEC document |
| December 23, 2021 Filed Feb 14, 2022 21:56 UTC |
Jakobovits AyaDirector
|
GiftCommon Stock | 39,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009370 · doc5.xml · nonDerivative · entry 6 Jakobovits Aya · CIK 0001823901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 372,345 F6 · kind: Represents a gift of Common Stock made on December 23, 2021. F5 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' son is the beneficiary. Read SEC document |
| December 23, 2021 Filed Feb 14, 2022 21:56 UTC |
Jakobovits AyaDirector
|
GiftCommon Stock | 39,791 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009370 · doc5.xml · nonDerivative · entry 5 Jakobovits Aya · CIK 0001823901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 372,343 F6 · kind: Represents a gift of Common Stock made on December 23, 2021. F3 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' daughter is the beneficiary. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.